Sanofi allegedly under inquiry for market manipulation - Breaking The News
Download our appPlay StoreApp Store

Sanofi allegedly under inquiry for market manipulation

EPA-EFE/IAN LANGSDON

The Parquet National Financier, a French judicial institution, began a preliminary probe against the country's pharmaceutical company Sanofi S.A. for alleged market manipulation, CNBC reported on Tuesday, citing a legal source.

According to the source, the investigation was launched in March 2023 on charges linked to Sanofi's possible market manipulation caused by the company's financial reports on the anti-allergy drug Dupixent released at the end of 2017.

The report claims that the company said it was completely unaware of this inquiry.

Related Stocks
Sanofi
Related News
Sanofi's Q3 net sales up by 15.7% to €13.44 billion
Sanofi SA announced on Friday that its revenue in the third quarter of the fiscal year 2024 saw an annual growth of 12.3% and 15.7% at the constant exchange rate (CER) to reach €13.44 billion.The pharmaceutical company's net income, calculated according to the International Financial Reporting Standards (IFRS), rose by 11.5% compared to the same trimester the year before to hit €2.81 billion. Its business net income went up by 17.6% at CER to...
Sanofi in talks with CD&R for 50% stake in Opella
Sanofi SA announced on Monday that it had entered into exclusive negotiations with Clayton, Dubilier & Rice (CD&R) to sell a 50% majority stake in Opella, its consumer health business. According to the statement, Sanofi will retain a significant minority stake, while CD&R will support Opella's growth as a global leader in the consumer health sector. The deal, valued at €16 billion, aims to enhance Opella's position with its flagship brands, such as Allegra and...
Sanofi net sales up 7.8% to €10.7B in Q2
Sanofi S.A. announced on Thursday that its net sales for the second quarter of its fiscal 2024 grew 7.8% year over year to reach €10.7 billion.In the reported trimester, on an annual basis, gross profit increased by 7.5% to stand at €7.9 billion, while business operating income jumped 3.2% to land at €2.8 billion. Furthermore, compared to the same timeframe a year prior, net income and earnings per share plummeted around 0.7% to €2.1 billion and €1.73,...
Novavax skyrockets 213.5% in premarket, highest in 16 months
Novavax Inc. shares continued to surge Friday in the premarket session in New York increasing more than 200% and reaching $14 per share, the highest it has traded since December 2022.Investors are showing high interest in the company with a $627.60 million market capitalization after the recent announcement of a co-exclusive agreement with Sanofi which will make its COVID-19 vaccine reach further markets.The biotechnology firm's stock...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.